Table 1 Clinicopathological characteristics for all patients’ primary tumors, as well as for the subgroup with PIK3CA mutation and the subgroup with no PIK3CA mutation.
All | Primary tumor with PIK3CA mutation | Primary tumor with no PIK3CA mutation | P-value mutation (mutation vs no mutation per characteristic) | |
|---|---|---|---|---|
N = 62* | N = 23** | N = 35** | ||
Tumor size | P = 0.30 | |||
Median, mm (range) | 24 (10–100) | 25 (10–60) | 24 (10–100) | |
Tumor stage | P = 0.84 | |||
pT1 | 23 (37.10%) | 7 (30.43%) | 14 (40.00%) | |
pT2 | 34 (54.84%) | 14 (60.87%) | 18 (51.43%) | |
pT3 | 5 (8.06%) | 2 (8.70%) | 3 (8.57%) | |
pN status | P = 0.000070 | |||
pN0 | 35 (56.45%) | 6 (26.09%) | 28 (80.00%) | |
pN1 | 15 (24.19%) | 11 (47.83%) | 3 (8.57%) | |
pN2 | 8 (12.90%) | 4 (17.39%) | 4 (11.43%) | |
pN3 | 4 (6.45%) | 2 (8.70%) | 0 (0.00%) | |
Lymph node status | P = 0.000088 | |||
Negative | 35 (56.45%) | 6 (26.09%) | 28 (80.00%) | |
Positive | 27 (43.55%) | 17 (73.91%) | 7 (20.00%) | |
TNM stage | P = 0.089 | |||
Stage 1 | 16 (25.81%) | 3 (13.04%) | 13 (37.14%) | |
Stage 2 | 34 (54.84%) | 14 (60.87%) | 18 (51.43%) | |
Stage 3 | 12 (19.35%) | 6 (26.09%) | 4 (11.43%) | |
Histological subtype | P = 0.75 | |||
Ductal | 43 (69.35%) | 15 (65.22%) | 26 (74.29%) | |
Lobular | 14 (22.58%) | 6 (26.09%) | 6 (17.14%) | |
Other | 5 (8.06%) | 2 (8.70%) | 3 (8.57%) | |
Histologic grade | P = 0.21 | |||
NHG1 | 9 (14.52%) | 5 (21.74%) | 4 (11.43%) | |
NHG2 | 28 (45.16%) | 12 (52.17%) | 15 (42.86%) | |
NHG3 | 24 (38.71%) | 5 (21.74%) | 16 (45.71%) | |
NA | 1 (1.61%) | 1 (4.35%) | 0 (0.00%) | |
ER, % | P = 0.64 | |||
Median, % (range) | 90 (5–100) | 90 (50–100) | 90 (5–100) | |
PR, % | P = 0.35 | |||
Median, % (range) | 40 (0–100) | 60 (0–100) | 40 (0–100) | |
PR status | P = 0.31 | |||
Negative (< 10%) | 14 (22.58%) | 3 (13.04%) | 9 (25.71%) | |
Positive (≥ 10%) | 35 (56.45%) | 16 (69.57%) | 18 (51.43%) | |
NA | 13 (20.97%) | 4 (17.39%) | 8 (22.86%) | |
PR status | P = 0.34 | |||
Negative (< 20%) | 16 (25.81%) | 4 (17.39%) | 10 (28.57%) | |
Positive (≥ 20%) | 33 (53.23%) | 15 (65.22%) | 17 (48.57%) | |
NA | 13 (20.97%) | 4 (17.39%) | 8 (22.86%) | |
Ki67, % | P = 0.018 | |||
Median, % (range) | 20 (1–95) | 15 (1–80) | 24 (1–95) | |
Ki67 status | P = 0.24 | |||
Low (< 15%) | 20 (32.26%) | 9 (39.13%) | 9 (25.71%) | |
High (≥ 15%) | 34 (54.84%) | 11 (47.83%) | 23 (65.71%) | |
NA | 8 (12.90%) | 3 (13.04%) | 3 (8.57%) | |
Ki67 status | P = 0.090 | |||
Low (< 20%) | 25 (40.32%) | 12 (52.17%) | 11 (31.43%) | |
High (≥ 20%) | 29 (46.77%) | 8 (34.78%) | 21 (60.00%) | |
NA | 8 (12.90%) | 3 (13.04%) | 3 (8.57%) | |
HER2 IHC | P = 0.17 | |||
0 | 37 (59.68%) | 16 (69.57%) | 18 (51.43%) | |
1 + | 11 (17.74%) | 4 (17.39%) | 6 (17.14%) | |
2 + | 9 (14.52%) | 1 (4.35%) | 8 (22.86%) | |
3 + | 2 (3.23%) | 0 (0.00%) | 2 (5.71%) | |
NA | 3 (4.84%) | 2 (8.70%) | 1 (2.86%) | |
HER2 status*** | P = 0.097 | |||
HER2-negative/zero | 37 (59.68%) | 16 (69.57%) | 18 (51.43%) | |
HER2-low | 22 (35.48%) | 5 (21.74%) | 16 (45.71%) | |
HER2-positive | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | |
NA | 3 (4.84%) | 2 (8.70%) | 1 (2.86%) | |
TIL score | P = 0.90 | |||
Median, % (range) | 5 (1–40) | 5 (1–40) | 5 (1–35) |
